Meet some of the executives behind some of San Diego's thriving technology and biotech companies, along with news about IP issues, the latest products and innovations.

  • Limiting liability in clinical trials: Non-lawyers, lawyers beware

    Clinical trials are the lifeblood of biotech. Finding the right service providers (CROs, safety, IVRS, consultants, contract manufacturers and many others), as well as the right clinical investigators and sites, results in a complex web of legal obligations and potential liabilities. Limitation of liability clauses can reduce a party's exposure if a contractual obligation is breached. More often, limitations of liability provisions are used to shift risk to the sponsor of the clinical trial. But, if your contracts are well negotiated and drafted, the risks can be carefully and fairly allocated between the parties in a balanced and reasonable manner. Because of the complexity of the legal relationships and liabilities found in clinical trials, this article is limited to a brief description of limitation of liability clauses, and their general strengths and weaknesses.

  • Biomimicry: Local companies borrow from nature to create better design

    When people think of art, they think of the Louvre. When people think of nature-inspired designs and solutions, they think of San Diego.

  • Innovative San Diego life sciences companies weather the storm

    Amid economic gloom, there are bright spots for San Diego life sciences innovators. Industry fundamentals remain favorable, technological advances continue to be made and $10 billion in funding from the National Institutes of Health was approved in the economic stimulus package signed by President Barack Obama. For the ag-biotech and clean energy cluster growing here, federally guaranteed loans may help underwrite construction of projects with new technologies in renewable energy at a time when debt markets are closed.

  • In tough recession, San Diego biotechs can partner their way forward

    The collapse of traditional financing markets has biotech executives in San Diego and the world over exploring alliances and creative collaborations as an alternative strategy to advance their products, or to simply keep the company alive until investor confidence in biotech returns.

  • Laboratory market poised for opportunity

    With 13.8 million square feet of inventory, San Diego County ranks as the third largest biotech hub in the United States behind Boston/Cambridge and the San Francisco Bay Area. This number will continue to grow due to the county's exceptional roster of educational and research institutions and recognition as a desirable place to live and work.

  • Eli Lilly signs lease with Veralliance Properties for Campus Pointe project

    Veralliance Properties is currently undertaking one of its largest and most ambitious building transformations in San Diego at its 465,000-square-foot Campus Pointe project located in the University Towne Center (UTC) area. The transformation has attracted biopharmaceutical corporation Eli Lilly and Co. (NYSE: LLY) to the site.

  • ROEL Construction, American Heart Association challenge corporate San Diego to Start! walking

    Heart disease and stroke continue to be the nation's No. 1 and 3 killers, and 142 million American adults -- 66 percent of Americans -- are overweight. Physical inactivity is a major risk factor for heart disease, and is a comparable risk to other modifiable risk factors such as high blood cholesterol, high blood pressure and smoking. About 70 percent of the American population engages in no regular leisure-time physical activity, which is defined as light-moderate activity for more than 30 minutes, five times a week, or vigorous activity (like brisk walking) for more than 20 minutes, three times a week.

  • Tips for managing a patent portfolio

    A comprehensive patent strategy requires managing all aspects of a patent portfolio, from correctly identifying inventors and their assignment obligations to tracking priority of claimed subject matter. Overlooking these issues can have detrimental effects on patentability, validity, enforceability and patent term. The following basic tips should avoid some of these pitfalls.

  • Future of life sciences: Transformation amid rising risk

    Charles Darwin once said, "It is not necessarily the strongest that survive or the most intelligent, but the one most responsive to change." The same can be said of the life sciences industry. For nearly a decade, life sciences companies have struggled against low productivity in research and development (R&D), loss of patent protection, competition from generics, skyrocketing costs, an ongoing talent shortage and diminishing corporate reputations.

  • Fresh start for biosimilars in 2009?

    In 2007, legislative initiatives to create a generic biologics pathway stalled before they got started. In fact, innovators and generics from the pharmaceutical and biotechnology industries could not even agree on an appropriate name for these controversial products, often referred to as "follow-on biologics," "biosimilars," "biogenerics" or "comparable biologic products." In 2007 and 2008, several divergent bills were proposed, but the efforts gave way to the presidential and congressional elections. 2009 has seen a resurrection of this debate.

Who's Who in Tech & Biotech

Roundtables

  • Funding biggest challenge for life sciences sector

    In 1960, when President Kennedy said he wanted U.S. astronauts on the moon by the end of the decade, it seemed impossible. But the government used this single-minded agenda as a policy guide, and in 1969 there was that famous giant leap for mankind.

Profiles

Archived Reports

Who's Who in Tech & Biotech - 2011

Learn about key people, innovations and trends in San Diego’s thriving tech and biotech industries.

Who's Who in Tech & Biotech - 2010

Find out Who's Who in Tech & Biotech as we profile a few executives turning local companies into regional success stories.

Who's Who in Tech & Biotech - 2008

Take a closer look at some of the leading CEOs turning local tech and biotech companies into regional success stories.

Who's Who in Tech & Biotech - 2006

Find out how high-tech and biotech companies continue to impact our economy in this annual report. We profile some of the local CEOs and feature a roundtable discussion hosted by Connect.